Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICA07 in advanced Parkinson's disease
NCT06821529Phase 1Not yet recruiting
- Sponsor
- iCamuno Biotherapeutics
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Autologous Induced Pluripotent Stem Cell-derived Dopamine Progenitor Cells in Parkinson's disease (PD), sponsored by iCamuno Biotherapeutics. Primary endpoint: Incidence and severity of Treatment-Emergent Adverse Events at 12 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
Autologous Induced Pluripotent Stem Cell-derived Dopamine Progenitor Cells
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06821529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821529.